GuidelineMaturitas2020
Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia.
Guideline in Maturitas, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.The Cochrane database of systematic reviews · 2023Pooled it
- Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards: A Systematic Review.JAMA network open · 2021Pooled it
- Association of hormone therapy and outcomes in COVID-19.Menopause (New York, N.Y.) · 2025Article
- Current use of estrogen-containing oral contraceptives or hormone therapy and risk of COVID-19 infection and hospitalization: a population-based cohort study.American journal of epidemiology · 2024Article
- Estrogen-modulating treatment among mid-life women and COVID-19 morbidity and mortality: a multiregister nationwide matched cohort study in Sweden.BMC medicine · 2024Article
- Estrogen-based hormonal therapy and the risk of thrombosis in COVID-19 patients.European journal of haematology · 2023Article
- Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.The Cochrane database of systematic reviews · 2023Review
- Premenopausal and postmenopausal women during the COVID-19 pandemic.Przeglad menopauzalny = Menopause review · 2022Review
- Hormonal therapies and venous thrombosis: Considerations for prevention and management.Research and practice in thrombosis and haemostasis · 2022Article
- Thromboembolism and Oral Contraceptives During the COVID-19 Pandemic: A Disproportionality Analysis Within the Spanish Pharmacovigilance Database.Drugs - real world outcomes · 2022Article
- Are sex hormones promising candidates to explain sex disparities in the COVID-19 pandemic?Reviews in endocrine & metabolic disorders · 2022Review
- Progestogen-only oral contraceptives.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2022Article
- Basic mechanisms of SARS-CoV-2 infection. What endocrine systems could be implicated?Reviews in endocrine & metabolic disorders · 2022Review
- Hormone Therapy in the Era of the COVID-19 Pandemic: A Review.Journal of menopausal medicine · 2022Review
- COVID-19 and hormonal contraception.Case reports in women's health · 2022Article
- Contraception in the COVID-19 pandemic: recommendations from the Korean society of contraception and reproductive health.Obstetrics & gynecology science · 2022Article
- Effects of the COVID-19 Pandemic on Gynecological Health: An Integrative Review.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2022Review
- Sex hormones and immune system: Menopausal hormone therapy in the context of COVID-19 pandemic.Frontiers in immunology · 2022Review
- An oral combined contraceptive user with elevated D-dimer post COVID-19: a case report.BMC women's health · 2021Article
- Contraceptive counseling during the pandemic: practical guidelines.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2021Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is associated with a systemic inflammatory response with activation of coagulation in symptomatic patients. The possibility of coagulopathies in peri- and postmenopausal women taking estrogen therapies makes it necessary to consider antithrombotic strategies, such as the use of low molecular weight heparins (LMWH) at specific prophylactic or treatment doses for each individual case, depending on the risk factors that each woman presents. For such reasons, a panel of experts from various Spanish scientific societies has met to develop usage recommendations for managing menopausal women taking menopausal hormone therapy (MHT) or combined hormonal contraception (CHC) during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.